Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.
相关临床试验
0
0 进行中
药物批准
1
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
- Revance and Teoxane announced FDA approval of RHA Redensity Eye for correcting moderate to severe tissue volume deficiencies in the infraorbital region in adults aged 22 or older. - The approval is supported by a 52-week pivotal study in which 93% of patients showed aesthetic improvement at 3 months, with results lasting up to 12 months without touch-ups. - RHA Redensity Eye is the first hyaluronic acid gel to use patient-reported outcomes as a co-primary endpoint in a U.S. clinical study for the infraorbital region. - The product demonstrated a favorable safety profile with no late-onset or serious treatment-related adverse events, granulomas, delayed inflammatory responses, or vascular occlusion.
- The FDA has approved RHA Dynamic Volume, a hyaluronic acid dermal filler, for cheek augmentation and correction of age-related midface contour deficiencies in adults 22 years and older. - A 52-week Phase III clinical trial demonstrated that RHA Dynamic Volume showed comparable effectiveness to Juvéderm Voluma XC, with patients requiring fewer treatment sessions and touch-ups to achieve similar outcomes. - Over 94% of participants reported natural-looking and feeling results at rest and in motion up to one year post-treatment, with no perception of restricted facial movement. - The product features Preserved Network Technology and will launch in Q1 2026 under its new name, previously known as RHA 4 Mepi.
- Dermata Therapeutics announced that XYNGARI achieved statistically significant results for all three co-primary endpoints in its Phase 3 STAR-1 trial for moderate-to-severe acne treatment at both 4 and 12 weeks. - The company raised $8.8 million in gross proceeds during the first half of 2025 to fund operations into the second quarter of 2026. - XYNGARI is a once-weekly topical treatment derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. - The company is evaluating next steps for the second Phase 3 STAR-2 trial, which would be followed by a 9-month extension study before filing a new drug application with the FDA.
- Dermata Therapeutics has received its second granted patent for DMT410, a novel topical botulinum toxin delivery system for hyperhidrosis treatment using Spongilla technology. - The Australian patent strengthens the company's global intellectual property portfolio for DMT410, which uses XYNGARI™ to create microchannels for needle-free intradermal botulinum toxin delivery. - DMT410 has shown promising efficacy and safety results in Phase 1 clinical trials for axillary hyperhidrosis, with a Phase 2a study planned using DAXXIFY® formulation. - The technology addresses high unmet medical needs in palmer and plantar hyperhidrosis treatment, potentially transforming patient care beyond current injection-based therapies.
- The cervical dystonia therapeutics market is poised for growth, driven by advancements in R&D and the emergence of novel treatment options. - Key pipeline drugs, including Daxibotulinumtoxin A from Revance Therapeutics and ABP-450 from AEON Biopharma, are expected to enter the market soon. - Current treatments focus on symptom management, but new therapies aim to address the underlying disease mechanisms for improved outcomes. - Several companies, including Ipsen and Allergan, are actively involved in developing innovative medications and devices for cervical dystonia.
